Payment overview · 2025
General Payments
$1,266.87
55 reported records · 20 companies
Healthcare provider profile · identity verified
Prema M Jacob, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOVELAND, CO · NPI 1487633533
Verified facts
What the public records show
CMS Open Payments records show Prema M Jacob, MD received $1,266.87 in general payments during 2025 across 55 reported records.
Lilly USA, LLC accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $220.52 | 17.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.93 | 14.6% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $145.82 | 11.5% | 10 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $118.38 | 9.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.22 | 4.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $59.23 | 4.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.68 | 4.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.09 | 4.3% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $47.00 | 3.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $46.86 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.27 | 3.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.22 | 3.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.05 | 2.8% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $26.51 | 2.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.59 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.33 | 1.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $19.80 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.58 | 1.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $19.56 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.23 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,257.22 | 54 |
| Education | $9.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $189.27 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $158.74 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $122.31 | 9 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $118.38 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $113.89 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $61.22 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $59.23 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.68 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.09 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.98 | 3 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $47.00 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.27 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $26.19 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 80 |
| Carvedilol | Carvedilol | 178 | 46 |
| Losartan Potassium | Losartan Potassium | 160 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 40 |
| Lisinopril | Lisinopril | 95 | 37 |
| Tramadol Hcl | Tramadol Hcl | 81 | 16 |
| Mounjaro | Tirzepatide | 79 | 13 |
| Metformin Hcl | Metformin Hcl | 60 | 20 |
| Atorvastatin Calcium | Atorvastatin Calcium | 54 | 17 |
| Omeprazole | Omeprazole | 51 | 12 |
| Trazodone Hcl | Trazodone Hcl | 51 | 19 |
| Gabapentin | Gabapentin | 50 | suppressed |
| Furosemide | Furosemide | 48 | 15 |
| Prednisone | Prednisone | 46 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 12 |
| Ozempic | Semaglutide | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 28 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Jardiance | Empagliflozin | 32 | 12 |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 12 |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,266.87 · 55 records | Lilly USA, LLC | AREXVY, BEXSERO, BOTOX, BREZTRI, CAPLYTA, FREESTYLE LIBRE 3, Fluad, Flucelvax, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NEXPLANON, OMNIPOD, OTEZLA, QULIPTA, REPATHA, REXULTI, SHINGRIX, SMARTVEST, SUBLOCADE, Saxenda, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, YUPELRI, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error